Peter Marks says Sarepta gene therapy pause ‘makes sense’news2025-07-18T19:05:54+00:00July 18th, 2025|Endpoints News|
FDA rejects expanded label for Roche’s Columvinews2025-07-18T18:17:56+00:00July 18th, 2025|Endpoints News|
FDA will ask Sarepta to stop selling Duchenne treatment, following patient deathsnews2025-07-18T17:20:49+00:00July 18th, 2025|Endpoints News|
Sarepta patient dies in study for limb-girdle muscular dystrophy, raising more safety concernsnews2025-07-18T01:23:15+00:00July 18th, 2025|Endpoints News|
Three takeaways from US senators’ report on pharma-telehealth relationshipsnews2025-07-17T19:01:18+00:00July 17th, 2025|Endpoints News|
FDA adcomm votes against GSK’s Blenrep in multiple myelomanews2025-07-17T18:29:49+00:00July 17th, 2025|Endpoints News|
Pharmaceutical exports from Ireland climb again as tariffs inch closernews2025-07-17T16:50:31+00:00July 17th, 2025|Endpoints News|
Bristol Myers, Pfizer launch DTC offering for Eliquis at 40% discountnews2025-07-17T15:57:45+00:00July 17th, 2025|Endpoints News|
UK government pledges “billions of pounds” for new research center in Essexnews2025-07-17T14:54:32+00:00July 17th, 2025|Endpoints News|
BioNTech strategy chief Richardson to leave for ‘new professional opportunities’news2025-07-17T13:28:59+00:00July 17th, 2025|Endpoints News|
